Ulcerative colitis market to hit $3 billion by 2020
BURLINGTON, Mass. — The market for drugs to treat ulcerative colitis will increase from 2010’s $1.7 billion to $3 billion in 2020, according to a new report by market research firm Decision Resources.
Key factors driving the market will include uptake of Humira (adalimumab), made by Abbott and Eisai, and Simponi (golimumab), made by Johnson & Johnson and Merck, as well as drugs currently under development, like Millennium’s vedolizumab and Pfizer’s tofacitinib. Markets included in the analysis were the United States, Germany, France, Italy, Spain, Japan and the United Kingdom.
"Currently in phase-3 of development for moderate to severe ulcerative colitis, but with scant robust clinical data at present to confirm positive phase-2 results, vedolizumab and tofacitinib will likely extend the treatment algorithm by offering — for the first time — additional lines of therapy for patients with inadequate response to the [tumor necrosis factor]-alpha inhibitors," Decision Resources analyst Kathrina Quinn said.
Reports: Teva developing Type 1 diabetes drug
NEW YORK — Israeli drug maker Teva Pharmaceutical Industries is developing a protein that could offer a new way to treat Type 1 diabetes, according to published reports.
Type 1 diabetes is an autoimmune disorder in which the immune system attacks the pancreas’s beta cells, but the drug, DiaPep277, stops that from happening, according to Bloomberg.
French drug maker Sanofi originally developed the drug but later gave up on it. Teva, which is developing the drug with Andromeda Biotech, has conducted a phase-3 trial of 457 patients and is planning to start a second one with 450, Bloomberg reported.
Apothecary Shops distributes GlowCap in pilot program
PHOENIX — Specialty pharmacy provider The Apothecary Shops is encouraging medication adherence with a cap for pill containers that cues patients with lights and sounds, the company said.
Apothecary Shop Wholesale is distributing GlowCap, a wireless prescription bottle cap, under a partnership with manufacturer Vitality and drug maker Novartis. The cap allows patients to plug the light in and begin receiving reminders the next day. The collaboration is part of a pilot program designed for patients using Novartis’ leukemia drug Tasigna (nilotinib) and malignant stromal tumor drug Gleevec (imatinib).
"Keeping patients on their medications is a significant problem in our country," Apothecary Shops VP clinical affairs Eric Sredzinski said. "At The Apothecary Shops, we are committed to finding and using the most effective means possible to keep our patients on their medications. That strategy underscores everything we do."